A Phase 1 interventional study of Ramucirumab in Solid Tumor, sponsored by Eli Lilly and Company. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-26.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial is testing ramucirumab (LY3009806) administered to Chinese participants with advanced solid tumors that are resistant to standard therapy or for whom no standard therapy is available. The purpose of this study is to evaluate how safe ramucirumab is and whether it causes any side effects. The study will also measure how much ramucirumab gets into the blood stream and how long it takes the body to get rid of it.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ramucirumab administered intravenously (IV) at escalating doses (6 milligrams per kilogram \[mg/kg\] up to 10 mg/kg) every 2-3 weeks for 6 weeks (1 Cycle). Treatment may continue until discontinuation criterion is met.
Biological: Ramucirumab
Administered IV.
Also known as: IMC-1121B, LY3009806
Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious Adverse Events (SAEs)
A summary of AEs and SAEs considered by the investigator to be drug-related is located in the Reported Adverse Events module. An AE is summarized if the onset date is on or after the first dose of study drug and within 30 days after the last dose, or it occurred before the first dose of study drug and worsened while on the therapy.
Time frame: Baseline through Study Completion (Up to 12 Weeks)
Pharmacokinetics: Maximum Concentration (Cmax) of Ramucirumab
Time frame: Cycle 1 & 2: Predose, End of Infusion, 0.5 hour (h) ,1h, 2h, 4h, 8h, 24h, 48h,72h or 96h, 168h, 264h, and 336h Postdose (and 504h Postdose Cohort 2 only)
Pharmacokinetics: Minimum Concentration (Cmin) of Ramucirumab
Time frame: Cycle 2-5: Predose
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab
Cycle 1 analysis performed: Area Under the Concentration-Time Curve Zero to Infinity (AUC\[0-∞\]); Cycle 2 analysis performed: Area Under the Concentration-Time Curve Over the Dosing Interval at Steady State (AUC\[τ,ss\])
Time frame: Cycle 1 & 2: Predose, End of Infusion, 0.5 hour (h) ,1h, 2h, 4h, 8h, 24h, 48h,72h or 96h, 168h, 264h, and 336h Postdose (and 504h Postdose Cohort 2 only)
Duration of Response
Participants achieved an objective response if they had a best overall response of complete response (CR) or partial response (PR). According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. For each participant who is not known to have died or to have had objective progression of disease as of the data-inclusion cut-off date for a particular analysis, duration of tumor response was to be censored at the date of the participant's last objective tumor assessment prior to that cut-off date.
Time frame: Time Between Meeting Response Criteria and Progressive Disease or Death Due to Any Cause (Up to 10 Weeks)
Duration of Stable Disease (SD)
Duration of SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters while on study. SD is measured at the start of the study drug until progressive disease or death due to any cause, whichever is first. Censoring occurred if a participant did not have a complete baseline disease assessment, initiated on another anti-cancer therapy (censored at the date of the last complete objective progression-free disease assessment before initiation of the new therapy), was not known to have died or had objective progression as of the data inclusion cutoff date for analysis.
Time frame: Baseline to Progressive Disease or Death Due to Any Cause (Up to 10 Weeks)
Time to Disease Progression
Time to progressive disease was measured from the start of study drug until progressive disease. Censoring occurred if a participant did not have a complete baseline disease assessment, initiated on another anti-cancer therapy (censored at the date of the last complete objective progression-free disease assessment before initiation of the new therapy), was not known to have died or had objective progression as of the data inclusion cutoff date for analysis.
Time frame: Baseline to Progressive Disease (Up to 10 Weeks)
Number of Participants With Anti-Ramucirumab Antibodies
A sample will be considered positive for circulating anti-ramucirumab antibodies if it exhibits a post-baseline antibody level that exceeds the upper 95% confidence interval of the mean determined from the normal anti-ramucirumab level seen in healthy untreated individuals. A participant will be considered to have an anti-ramucirumab response if there are 2 consecutive positive samples or if the final sample tested is positive.
Time frame: Cycle 1: Pre-infusion, Cycle 2: Pre-infusion, Cycle 3: Pre-infusion
Number of Participants With Best Objective Response (BOR)
Participants achieved disease control if they had a BOR of CR, PR or SD. Progressive Disease (PD) and those participants which were Not Evaluable (NE) were also reported. According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. SD was neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started.
Time frame: Baseline to Progressive Disease or Participant Stopped Study (Up to 10 Weeks)
| Milestone | Cohort 1 - 6 mg/kg/2w Ramucirumab | Cohort 2 - 10 mg/kg/3w Ramucirumab | Cohort 3 - 8 mg/kg/2w Ramucirumab |
|---|---|---|---|
| Started | 6 | 10 | 12 |
| Received at least 1 dose of study drug | 6 | 10 | 12 |
| Completed | 6 | 10 | 12 |
| Not completed | 0 | 0 | 0 |
A summary of AEs and SAEs considered by the investigator to be drug-related is located in the Reported Adverse Events module. An AE is summarized if the onset date is on or after the first dose of study drug and within 30 days after the last dose, or it occurred before the first dose of study drug and worsened while on the therapy.
| Participants | Cohort 1: 6 mg/kg/2w Ramucirumab | Cohort 2: 10 mg/kg/3w Ramucirumab | Cohort 3: 8 mg/kg/2w Ramucirumab |
|---|---|---|---|
| Drug-Related Adverse Event | 4 | 8 | 10 |
| Serious Adverse Event | 0 | 1 | 0 |
| microgram/milliliter (µg/mL) | Cohort 1: 6 mg/kg/2w Ramucirumab | Cohort 2: 10 mg/kg/3w Ramucirumab | Cohort 3: 8 mg/kg/2w Ramucirumab |
|---|---|---|---|
| Cycle 1 (n = 6, 9, 12) | 155 ± 13 | 186 ± 22 | 190 ± 39 |
| Cycle 2 (n = 1, 6, 8) | NA ± NA | 219 ± 22 | 239 ± 19 |
| µg/mL | Cohort 1: 6 mg/kg/2w Ramucirumab | Cohort 2: 10 mg/kg/3w Ramucirumab | Cohort 3: 8 mg/kg/2w Ramucirumab |
|---|---|---|---|
| Cycle 2 (n = 5, 8, 10) | 36.9 ± 35 | 29.5 ± 90 | 59.7 ± 26 |
| Cycle 3 (n = 1, 2, 5) | NA ± NA | NA ± NA | 68.7 ± 28 |
| Cycle 4 (n = 1, 2, 4) | NA ± NA | NA ± NA | 79.6 ± 26 |
| Cycle 5 (n = 0, 3, 4) | NA ± NA | 56.5 ± 17 | 92.5 ± 19 |
Cycle 1 analysis performed: Area Under the Concentration-Time Curve Zero to Infinity (AUC\[0-∞\]); Cycle 2 analysis performed: Area Under the Concentration-Time Curve Over the Dosing Interval at Steady State (AUC\[τ,ss\])
| Microgram*day/milliliter (µg*day/mL) | Cohort 1: 6 mg/kg/2w Ramucirumab | Cohort 2: 10 mg/kg/3w Ramucirumab | Cohort 3: 8 mg/kg/2w Ramucirumab |
|---|---|---|---|
| Cycle 1 AUC(0-∞) (n = 5, 7, 7) | 870 ± 14 | 1430 ± 31 | 1350 ± 9 |
| Cycle 2 AUC(τ,ss) (n = 1, 6, 8) | NA ± NA | 1630 ± 32 | 1540 ± 16 |
Participants achieved an objective response if they had a best overall response of complete response (CR) or partial response (PR). According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. For each participant who is not known to have died or to have had objective progression of disease as of the data-inclusion cut-off date for a particular analysis, duration of tumor response was to be censored at the date of the participant's last objective tumor assessment prior to that cut-off date.
| Months | Cohort 1: 6 mg/kg/2w Ramucirumab | Cohort 2: 10 mg/kg/3w Ramucirumab | Cohort 3: 8 mg/kg/2w Ramucirumab |
|---|---|---|---|
| Duration of Response | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
Duration of SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters while on study. SD is measured at the start of the study drug until progressive disease or death due to any cause, whichever is first. Censoring occurred if a participant did not have a complete baseline disease assessment, initiated on another anti-cancer therapy (censored at the date of the last complete objective progression-free disease assessment before initiation of the new therapy), was not known to have died or had objective progression as of the data inclusion cutoff date for analysis.
| Months | Cohort 1: 6 mg/kg/2w Ramucirumab | Cohort 2: 10 mg/kg/3w Ramucirumab | Cohort 3: 8 mg/kg/2w Ramucirumab |
|---|---|---|---|
| Duration of Stable Disease (SD) | NA (NA to NA) | 5.68 (2.79 to 12.22) | 5.29 (2.92 to 6.87) |
Time to progressive disease was measured from the start of study drug until progressive disease. Censoring occurred if a participant did not have a complete baseline disease assessment, initiated on another anti-cancer therapy (censored at the date of the last complete objective progression-free disease assessment before initiation of the new therapy), was not known to have died or had objective progression as of the data inclusion cutoff date for analysis.
| Months | Cohort 1: 6 mg/kg/2w Ramucirumab | Cohort 2: 10 mg/kg/3w Ramucirumab | Cohort 3: 8 mg/kg/2w Ramucirumab |
|---|---|---|---|
| Time to Disease Progression | 1.41 (1.35 to NA) | 3.38 (1.28 to 8.21) | 3.94 (1.22 to 5.55) |
A sample will be considered positive for circulating anti-ramucirumab antibodies if it exhibits a post-baseline antibody level that exceeds the upper 95% confidence interval of the mean determined from the normal anti-ramucirumab level seen in healthy untreated individuals. A participant will be considered to have an anti-ramucirumab response if there are 2 consecutive positive samples or if the final sample tested is positive.
| Participants | Cohort 1: 6 mg/kg/2w Ramucirumab | Cohort 2: 10 mg/kg/3w Ramucirumab | Cohort 3: 8 mg/kg/2w Ramucirumab |
|---|---|---|---|
| Number of Participants With Anti-Ramucirumab Antibodies | 0 | 0 | 0 |
Participants achieved disease control if they had a BOR of CR, PR or SD. Progressive Disease (PD) and those participants which were Not Evaluable (NE) were also reported. According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. SD was neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started.
| Participants | Cohort 1: 6 mg/kg/2w Ramucirumab | Cohort 2: 10 mg/kg/3w Ramucirumab | Cohort 3: 8 mg/kg/2w Ramucirumab |
|---|---|---|---|
| Complete Response (CR) | 0 | 0 | 0 |
| Partial Response (PR) | 0 | 0 | 0 |
| Stable Disease (SD) | 3 | 7 | 8 |
| Progressive Disease (PD) | 3 | 3 | 3 |
| Not Evaluable (NE) | 0 | 0 | 1 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 - 6mg/kg/2w Ramucirumab | — | 1/6 (16.7%) | 6/6 (100%) |
| Cohort 2 - 10mg/kg/3w Ramucirumab | — | 2/10 (20%) | 10/10 (100%) |
| Cohort 3 - 8mg/kg/2w Ramucirumab | — | 1/12 (8.3%) | 12/12 (100%) |
| Event | Cohort 1 - 6mg/kg/2w Ramucirumab | Cohort 2 - 10mg/kg/3w Ramucirumab | Cohort 3 - 8mg/kg/2w Ramucirumab |
|---|---|---|---|
| FatigueGeneral disorders | 1/6 | 0/10 | 0/12 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/6 | 1/10 | 0/12 |
| Blood bilirubin increasedInvestigations | 0/6 | 1/10 | 0/12 |
| Impaired gastric emptyingGastrointestinal disorders | 0/6 | 0/10 | 1/12 |
| Event | Cohort 1 - 6mg/kg/2w Ramucirumab | Cohort 2 - 10mg/kg/3w Ramucirumab | Cohort 3 - 8mg/kg/2w Ramucirumab |
|---|---|---|---|
| FatigueGeneral disorders | 6/6 | 8/10 | 5/12 |
| HypertensionVascular disorders | 3/6 | 7/10 | 5/12 |
| Aspartate aminotransferase increasedInvestigations | 2/6 | 5/10 | 7/12 |
| ConstipationGastrointestinal disorders | 3/6 | 1/10 | 1/12 |
| Alanine aminotransferase increasedInvestigations | 2/6 | 5/10 | 5/12 |
| Decreased appetiteMetabolism and nutrition disorders | 2/6 | 5/10 | 3/12 |
| DizzinessNervous system disorders | 3/6 | 1/10 | 3/12 |
| ProteinuriaRenal and urinary disorders | 3/6 | 3/10 | 6/12 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/6 | 2/10 | 0/12 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 3/6 | 3/10 | 1/12 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(Years) | Cohort 1 - 6 mg/kg/2w Ramucirumab | Cohort 2 - 10 mg/kg/3w Ramucirumab | Cohort 3 - 8 mg/kg/2w Ramucirumab | Total |
|---|---|---|---|---|
| Mean | 51.20 ± 9.060 | 52.92 ± 9.509 | 58.18 ± 9.444 | 54.80 ± 9.536 |
| Sex: Female, Male(Participants) | Cohort 1 - 6 mg/kg/2w Ramucirumab | Cohort 2 - 10 mg/kg/3w Ramucirumab | Cohort 3 - 8 mg/kg/2w Ramucirumab | Total |
|---|---|---|---|---|
| Female | 4 | 3 | 7 | 14 |
| Male | 2 | 7 | 5 | 14 |
| Race (NIH/OMB)(Participants) | Cohort 1 - 6 mg/kg/2w Ramucirumab | Cohort 2 - 10 mg/kg/3w Ramucirumab | Cohort 3 - 8 mg/kg/2w Ramucirumab | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 6 | 10 | 12 | 28 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort 1 - 6 mg/kg/2w Ramucirumab | Cohort 2 - 10 mg/kg/3w Ramucirumab | Cohort 3 - 8 mg/kg/2w Ramucirumab | Total |
|---|---|---|---|---|
| China | 6 | 10 | 12 | 28 |
The record gives a start of Nov 2012, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab